{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fmint-primer.simplecast.com%2Fepisodes%2Fmalaria-gets-its-second-vax-why-its-momentous-U3D9uGRo","width":444,"version":"1.0","type":"rich","title":"Malaria Gets its Second Vax: Why it’s Momentous","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/ae6533df-095e-4fef-b7ef-69ea44f76a8c/b2d564be-3ff3-410d-8a4a-b471672ec439/mint-primer.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/1b31b757-effe-4af5-ac54-94a14ad26ef9\" height=\"200\" width=\"100%\" title=\"Malaria Gets its Second Vax: Why it’s Momentous\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":" A malaria vaccine developed by Oxford University and Serum Institute of India (SII) has been recommended for large-scale use by the World Health Organization (WHO). The R21/Matrix-M—only the second malaria jab—has shown up to 75% efficacy."}